

# Liver imaging the revolution

Valérie Vilgrain


*Hôpital Beaujon, Paris, France*




**At the Beginning of the story**

# Radiology in the 1970s

US




*Garrett Radiology 1976*




*Taylor Radiology 1976*

CT



*Philips Radiology 1975*



*Bryan Radiology 1977*

# Radiology in the 1980s

MRI



## Nuclear magnetic resonance imaging of the liver and pancreas

---

Peter L. Davis, M.D.

Albert A. Moss, M.D.

Henry I. Goldberg, M.D.

David D. Stark, M.D.

Alexander R. Margulis, M.D.

*Radiology* 1984






*Chronic liver disease*  
*Tumor detection*  
*Tumor characterization*  
*Tumor response*




**Morphological imaging**






# Chronic liver disease






Cirrhosis  
Non cirrhotic:  
Portal cavernoma  
Budd-Chiari  
Biliary



# Chronic liver disease






Cirrhosis  
Non cirrhotic:  
Portal cavernoma  
Budd-Chiari  
Biliary








# Chronic liver disease






Cirrhosis  
Non cirrhotic:  
Portal cavernoma  
Budd-Chiari  
Biliary







# Chronic liver disease




Cirrhosis  
Non cirrhotic:  
Portal cavernoma  
Budd-Chiari  
Biliary



# Tumor screening


- What are the clinical needs?
  - Impact on patient management
  - Impact on patient survival



- Which patients
  - High risk patients: chronic liver disease (HCC)

- Which imaging technique?

- Widely performed
- Non invasive



# Liver tumor staging

- What are the clinical needs?
  - Impact on patient management
  - Impact on patient survival
- Which patients
  - Oncologic patients
  - Surgical resection (colorectal liver metastases)

Maarten Christian Niekel, MSc  
Shandra Bipat, PhD  
Jaap Stoker, MD, PhD

2010

**Diagnostic Imaging of Colorectal Liver Metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A Meta-Analysis of Prospective Studies Including Patients Who Have Not Previously Undergone Treatment<sup>1</sup>**

Radiology

## **Conclusion:**

MR imaging is the preferred first-line modality for evaluating colorectal liver metastases in patients who have not previously undergone therapy. FDG PET can be used as the second-line modality. The role of FDG PET/CT is not yet clear owing to the small number of studies.

# Liver tumor staging

## liver metastases

***Conventional***

***DW-MR***

***HB contrast agents***







*T1, T2*

*Lesion enhancement*

*Restricted  
diffusion*

*Hypointensity on  
HB phase*





# Liver tumor staging

## liver metastases

- Meta-analysis on liver mets
  - 39 articles (1989 patients, 3854 liver metastases)

MR	Sensitivity (%)
diffusion	87.1%
HB phase using Gadoteric acid	90.6%
both	95.5%

### Higher sensitivity with combined DW and HB phase

Only colorectal liver mets

Liver mets < 1 cm

Neoadjuvant chemotherapy

Histopathology alone as reference method

Translation in  
clinical practice ?

# Liver tumor staging

## liver metastases

**VALUE study:** 360 patients with suspected colorectal cancer liver metastases who had either *gadoxetic acid enhanced MRI*, *MRI with extracellular contrast medium* or *contrast-enhanced CT* as a first-line imaging method in patients

	Gadoxetic A MR	Regular MR	CT
Further imaging	0%	17%	39.3%
Diagnostic confidence	98.3%	85.7%	65.2%
Surgical changes	28%	32%	47%

# Tumor characterization

- What are the clinical needs?
  - Impact on patient management in all patients

***Incidental lesions***

***Oncologic pts***

***Chronic liver diseases***

*Mostly  
benign  
f/U?*

*Rarely  
malignant*

*Mostly  
liver mets*


*some  
benign  
50%  
<2cm*

*HCC*


*Benign  
nodules*

Hemangioma  
FNH  
Adenoma


# Tumor characterization



HCC



FNH






hemangioma

Lesion  
enhancement



**CT**  
**MRI**  
**CEUS**






# Tumor characterization





Fat  
Hemorrhage  
Iron  
Highly cellular  
Hepatocellular






# Tumor characterization





Fat  
Hemorrhage  
Iron  
Highly cellular  
Hepatocellular



# Tumor characterization






Fat  
Hemorrhage  
Iron  
Highly cellular  
Hepatocellular







# Tumor characterization






Fat  
Hemorrhage  
Iron  
Highly cellular  
Hepatocellular







# Tumor characterization



Fat  
Hemorrhage  
Iron  
Highly cellular  
Hepatocellular





**MRI**





# Tumor response

## RECIST criteria

Complete response



Partial response



Progression



# Can we push the morphological imaging forward?

- Probably marginally
- The revolution is elsewhere


Quantitative imaging  
Multiparametric imaging  
Multimodal approach  
3D assessment

RSNA  
Radiological Society of North America

# Radiology *Select* Imaging the Liver

ISSN 0895-1963/19/07/07  
Volume 7

A continuing series of selected Radiology articles that highlight developments in imaging science, techniques, and clinical practice.



Guest Editors:  
Yoshinao Ueda, MD  
Munira Perrot, MD

## Radiology Select



■ hepatocellular tumors

■ DW-MR

■ Quantitative imaging

■ hepatobiliary MR agents

■ interventional



**quantitative imaging**

# Quantitative imaging

## the big four

- Liver volume
- Fat quantification
- Iron quantification
- Liver stiffness




*Widely used*

*Highly reproducible*



*Validated*

*Clinical impact*

# Quantitative imaging liver volume




- Entire liver
  - Prognostic factor in fulminant hepatic failure
- Future remnant liver
  - critical predictor of perioperative outcomes major liver resection
  - Indicates portal vein embolization




- Tumor volume

# Quantitative imaging fat




- NAFLD is the most frequent cause for referral for chronic liver disease and an increasing cause of HCC
- In patients undergoing liver resection, NAFLD increases the risk of postop complications and death
- In liver transplantation, presence of steatosis in the graft increases the risk of graft failure


# Quantitative imaging fat with MRI




- MR spectroscopy
  - direct measure of the chemical composition of tissue
- chemical-shift techniques (T1 GE)
  - *in-phase/out-of-phase* (Dixon in 1984)





– *Current Dixon-type sequences: Decomposition of*



an



o











Fat-water separation sequences for quantification

*Steatosis  
Mild iron overload*

$$PDFF = \frac{\rho_f}{\rho_w + \rho_f}$$

*No steatosis  
Mild iron overload*



# Quantitative imaging liver stiffness




*Increased stiffness correlates with the amount of fibrosis*

- Treatment planning in chronic viral hepatitis depends on the degree of fibrosis
- In patients undergoing liver resection, marked fibrosis and cirrhosis increase the risk of postop complications and death
- Liver and spleen stiffness are correlated to the degree of portal hypertension

# Quantitative imaging liver stiffness

- Ultrasound

- Transient Elastography (TE)
- Integrated onto conventional US
  - Acoustic Radiation Force Impulse (ARFI)
  - ShearWave™ Elastography



• MR imaging

	Fibroscan	Ultrasound	MRI
availability	+++	+++	+
dimension	1D	2D	3D
performance	++	+++	+++
Other data	steatosis	All US	All MRI
limitations	Ascites, obesity	few	few

OPEN ACCESS Freely available online


2014 PLOS ONE

**Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease**

Jack X. Q. Pang<sup>1,2</sup>, Scott Zimmer<sup>3</sup>, Sophia Niu<sup>3</sup>, Pam Crotty<sup>1</sup>, Jenna Tracey<sup>1</sup>, Faruq Pradhan<sup>1</sup>, Abdel Aziz M. Shaheen<sup>1</sup>, Carla S. Coffin<sup>1</sup>, Steven J. Heitman<sup>1,2</sup>, Gilaad G. Kaplan<sup>1,2</sup>, Mark G. Swain<sup>1</sup>, Robert P. Myers<sup>1,2\*</sup>



HEPATOLOGY Official Journal of the American Association for the Study of Liver Diseases

2015 

**Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients With Transient Elastography-Defined Subclinical Cirrhosis**

Mi Na Kim,<sup>1</sup> Seung Up Kim,<sup>1,2</sup> Beom Kyung Kim,<sup>1,2</sup> Jun Yong Park,<sup>1,2</sup> Do Young Kim,<sup>1,2</sup> Sang Hoon Ahn,<sup>1,2,5</sup> Ki Jun Song,<sup>3</sup> Young Nyun Park,<sup>4</sup> and Kwang-Hyub Han<sup>1,2,5</sup>


# Quantitative imaging

other

*May be used currently  
poorly reproducible  
Insufficiently validated*


- Diffusion-weighted MRI

- ADC, IVIM technique



- Perfusion parameters


- Blood flow, blood volume...



- Fingerprinting

- Simultaneous measure of T1 and T2

- Liver function: gadoxetic acid





# Conclusion

- Liver imaging is everyday morphological and multimodal
- The role of imaging biomarkers is increasing but few are validated
- Tomorrow imaging will be quantitative and multiscale: Radiomics
- Artificial Intelligence in Imaging is the next revolution and will change the practice